2-azabicyclo(2.2.1)hept-5-en-3-one: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 548678 |
SCHEMBL ID | 548616 |
MeSH ID | M0172621 |
Synonym |
---|
3-azabicyclo[2.2.1]hept-5-en-2-one |
49805-30-3 |
A1359 |
2-azabicyclo[2.2.1]hept-5-en-3-one |
EN300-82926 |
(-)-2-azabicyclo[2.2.1]hept-5-en-3-one |
A827858 |
AKOS006223009 |
2-azabicyclo(2.2.1)hept-5-en-3-one |
FT-0643143 |
FT-0600312 |
FT-0601151 |
(-)-(1r,4s)-2-azabicyclo[2.2.1]hept-5-en-3-one |
SCHEMBL548616 |
2-azabicyclo[2.2.1]hept-5-en-3-one # |
2-azabicyclo[2.2.1]hept-5-en-3-one, (1s)- |
J-500009 |
(-)-2-azabicyclo[2,2,1]hept-5-en-3-one |
(+/-)-2-azabicyclo [2.2.1]hept-5-en-3-one |
(+/-)-2-azabicyclo[2.2.1 ]hept-5-en-3-one |
(-)-2-azabicyclo [2.2.1]hept-5-en-3-one |
(-)-2-azabicyclo [2.2.1] hept-5-en-3one |
racemic 2-aza bicyclo[2.2.1]hept-5-ene-3-one |
J-650015 |
(1r)-(-)-2-azabicyclo[2,2,1]hept-5-en-3-one |
Q-200006 |
J-650014 |
J-650392 |
azabicyclo[2.2.1]hept-5-en-3-one |
rac 2-azabicyclo[2.2.1]hept-5-en-3-one |
(r,s)-2-azabicyclo(2.2.1)hept-5-en-3-one |
ec 421-830-3 |
AC-6114 |
3-oxo-2-azabicyclo[2.2.1]hept-5-ene |
SY004961 |
CS-W019811 |
DTXSID40868505 |
61865-48-3 |
SY096758 |
DS-11069 |
SB18483 |
SB18484 |
SB11075 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (14.29) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 4 (57.14) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.14) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (14.29%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (85.71%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |